Quick Answer
ArriVent BioPharma, Inc. reported Diluted EPS of $4.32 per share (loss) for fiscal year 2025.
ArriVent BioPharma, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$4.32 | -68.8% |
| 2024 | -$2.56 | +92.1% |
| 2023 | -$32.38 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.83 | -36.1% | +7.8% |
| June 30, 2025 | -$0.90 | -38.5% | +52.6% |
| March 31, 2025 | -$1.90 | -171.4% | -211.5% |
| September 30, 2024 | -$0.61 | +88.9% | +6.2% |
| June 30, 2024 | -$0.65 | +94.0% | +7.1% |
| March 31, 2024 | -$0.70 | +92.6% | +87.3% |
| September 30, 2023 | -$5.52 | — | +48.8% |
| June 30, 2023 | -$10.79 | — | -14.2% |
- ArriVent BioPharma, Inc. showed a decrease of -68.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2023–2025 period, ArriVent BioPharma, Inc.’s diluted eps has grown by 86.7% (from $32.38 per share (loss) to $4.32 per share (loss)).
- The most recent figure is from ArriVent BioPharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: